Obesity and Insulin Resistance Research Findings

The research reported in the journal Science Metabolic discovered a dangerous loop where a high-fat meal causes regional lymphatic dysfunction, then contributes to belly fat storage. For the first time, scientists have demonstrated that gastrointestinal lymphatic insufficiency is a possible source of overweight and insulin sensitivity and a treatment option.

Obesity and Insulin Resistance Research Findings

To date, diabetes experts believe that obesity has a direct link to diabetes, and hence people with this disease used to be provided with insulin. However, after a certain level, they become insulin resistant which leads to poor medical conditions over a period.

 Obesity and Insulin Resistance Research Findings

Experts in this field carried out the research which explains this link and how the body becomes resistant to insulin. The outcomes of the same will be highly beneficial to many people as they can be provided with drugs to make insulin work as expected in the body.

Therapy of the intestinal lymph system with vessels and nodes COX-2 antagonist is demonstrated to regulate lymph vascular shape, prevent obesity, and cure insulin intolerance & hepatic insulin in type 2 diabetic patients. Importantly, the research suggests that interfering with this process by suppressing systems linked to lymph function could be a therapy for overweight and related metabolism illness.

A high-fat meal encouraged the creation of different afferent lymph systems, which developed in a very disordered way, as revealed in pre-clinical mice. These convoluted, branch arteries preferred to spill lymph system into the deep fat in the belly, prompting the establishment of diabetes. Lymphatic water is abundant in stomach fatty compounds and pro-inflammatory cytokines.

“In this study, we were able to identify for the first time a molecular reason why accumulation around the belly fat is associated with greater rates of metabolic disease such as type 2 diabetes than fat accumulation in other parts of the body,” stated Associate Professor Trevaskis.

A group of scientists from Melbourne’s Monash Research center of Pharmaceutical Sciences (MIPS), including Senior Lecturer Natalie Trevaskis, Prof Porter, and Comment Research Fellow Enyuan Cao, led the study in cooperation with PureTech Health, a US diagnostic biotechnologies business specializing in the discovery, development, and commercialism of differentiated therapies.

“We were able to demonstrate that a high-fat diet causes mesenteric lymphatic malfunction, which increases abdominal fat deposition and insulin resistance.”

“The findings of ex vivo tests employing clinical samples suggest that similar findings also apply to humans.”

The MIPS group created the GlyphTM drug carrier technique, which was licensed to PureTech in early 2017. Following then, MIPS & PureTech experts collaborated better to improve the system. The utilization of PureTech’s GlyphTM active metabolite software network, which would be specially intended to transport specific molecular medications straight into the intestinal lymphatic absorbed after oral delivery, is critical to the report’s effectiveness.

Because it delivered the COX-2 antagonist precisely to wherever it was required in the sigmoid lymphatic vessels, the lymph target technique was critical in the latest research for interrupting the process wherein meridian lymph malfunction leads to the formation of belly obesity.

“What’s remarkable about this study is that when the COX-2 inhibitor was delivered directly to the mesenteric lymphatics with our Glyph technology platform, it was able to meaningfully repattern the chaotic lymphatic structure in obese mice and that repatterning was accompanied by a substantial decrease in both weight gain and insulin resistance,” said PureTech’s Chief Scientific Officer, Joseph B.

This brings a glimpse of the seriousness on obesity matter.  A little seriousness towards your health may bring a joyful future.

“We are excited to continue our long-standing collaboration with the Monash team to expand on this intriguing study and uncover and advance other potential therapeutic applications for this platform,” says the company.

Leave a Comment

About Us

The Nuherald is an ‘everything under one roof’ news portal that provides you with the latest updates and news from the sports, entertainment, tech, health, and business world. We are one among the members of the renowned digital media network, Globe-News Network.

© 2024 TheNuHerald & The GlobeNews Network